Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

VolitionRx Limited First Quarter 2024 Financial Results and Business Update

Monday, May 13, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: VolitionRx Limited has released its financial results for the first quarter of 2024, highlighting a collaboration with Sysmex and the filing of a new patent for its Nu.Q® NETs Test. The video accompanying the results features insights from CEO Cameron Reynolds and CFO Terig Hughes. These developments indicate ongoing progress in their business strategy.
Price reaction · baseline $17.55 (2024-05-13 close) · hit after-hours · 1 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
-14.5%
day 1
-10.3%
day 3
-12.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • VolitionRx reported its first quarter 2024 financial results.
  • The company announced a collaboration with Sysmex.
  • A new patent was filed for the Nu.Q® NETs Test.

Full Press Release Details

A short video to accompany the first quarter 2024 results for Volition with Group Chief Executive Officer, Cameron Reynolds, and Chief Financial Officer, Terig Hughes.

Related Articles

• Press Releases VolitionRx Announces Collaboration with Sysmex
• Press Releases VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring

VolitionRx Announces Collaboration with Sysmex

VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What were the highlights of VolitionRx's Q1 2024 results?

VolitionRx announced a collaboration with Sysmex and filed a new patent for its Nu.Q® NETs Test.

Who presented the Q1 2024 results for VolitionRx?

The results were presented by Group CEO Cameron Reynolds and CFO Terig Hughes.

What is the Nu.Q® NETs Test related to?

The Nu.Q® NETs Test is designed for Ebola triage and treatment monitoring.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare VolitionRx financial results Sysmex Nu.Q® NETs Test
Last updated: May 13, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk